Vaxil Announces Private Placement Extension
26 nov. 2019 16h02 HE
|
Vaxil Bio Ltd.
Not for distribution by US newswire or in United States NESS-ZIONA, Israel, Nov. 26, 2019 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative...
Vaxil’s Annual and Special General Meeting
04 nov. 2019 16h05 HE
|
Vaxil Bio Ltd.
Not for distribution by US newswire or in United States TORONTO, Nov. 04, 2019 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), announces that at the Company's...
Vaxil Announces Private Placement Extension
30 oct. 2019 10h27 HE
|
Vaxil Bio Ltd.
Not for distribution by US newswire or in United States NESS-ZIONA, Israel, Oct. 30, 2019 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative...
Vaxil Announces Private Placement
10 sept. 2019 10h12 HE
|
Vaxil Bio Ltd.
Not for distribution by US newswire or in United States NESS-ZIONA, Israel, Sept. 10, 2019 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative...
Vaxil Appoints New Chairman
30 août 2019 09h00 HE
|
Vaxil Bio Ltd.
Not for distribution by US newswire or in United States NESS-ZIONA, Israel, Aug. 30, 2019 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (TSX VENTURE: VXL), an innovative immunotherapy biotech focused on...
Vaxil Bio Licenses P-Esbp for Targeted Cancer Therapy from BGN Technologies, the Technology Transfer Company of Ben-Gurion University, Israel
28 août 2019 09h00 HE
|
Vaxil Bio Ltd.
NESS-ZIONA, Israel, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Vaxil Bio Ltd (TSX VENTURE: VXL), a biotech company focusing on innovative immunotherapy treatments for cancer and infectious...
Vaxil Granted Significant US Patent for Anti-Infective Vaccines
21 mai 2019 08h00 HE
|
Vaxil Bio Ltd.
NESS-ZIONA, Israel, May 21, 2019 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (TSX VENTURE: VXL), an Israeli biotech focused on innovative immunotherapy treatments for cancer and infectious diseases, is...
Vaxil Appoints Veteran Pharma Executive David Goren as CEO
06 sept. 2018 08h30 HE
|
Vaxil Bio Ltd.
NESS-ZIONA, ISRAEL, Sept. 06, 2018 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (TSX VENTURE: VXL), an Israeli biotech focused on innovative immunotherapy treatments for cancer and infectious diseases, is...
Israeli Cancer Research Firm Vaxil Granted 9th Patent for Immunotherapy Treatment
03 mai 2018 08h30 HE
|
Vaxil Bio Ltd.
ISRAEL and TORONTO, May 03, 2018 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (TSX VENTURE:VXL), a cancer research biotechnology company focused on innovative immunotherapy treatments, has been granted...
Vaxil Granted First U.S. Patent for Its Cancer Immunotherapy Antibody Platform
01 mars 2018 08h30 HE
|
Vaxil Bio Ltd.
NESS-ZIONA, ISRAEL--(Marketwired - March 01, 2018) - VAXIL BIO LTD. (TSX VENTURE: VXL), an innovative Israeli cancer research company focused on immunotherapy, is pleased to announce that it has...